Cutler Group’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Cutler Group’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-2,200	Closed	-$2K	–	6647
2020 Q4	$2K	Buy	+2,200	New	+$194K	﹤0.01%	4328
2020 Q2	–	Sell	-6,500	Closed	-$16K	–	5146
2020 Q1	$16K	Buy	6,500 +3,500	+117%	+$178K	﹤0.01%	2473
2019 Q4	$7K	Buy	+3,000	New	+$149K	﹤0.01%	2890

Cutler Group's EIDX Position: Q1 2021 in Review

Cutler Group sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 170 shares — an estimated $22K sold.

Cutler Group first reported a position in EIDX in Q4 2019 and held it in 3 quarters. The position peaked at $344K in Q4 2019. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

Cutler Group reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Cutler Group sold 170 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $22K.
Cutler Group first reported a position in Eidos Therapeutics, Inc. Common Stock in Q4 2019 and held it in 3 quarters.
Cutler Group's Eidos Therapeutics, Inc. Common Stock position peaked at $344K in Q4 2019.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Cutler Group's 13F filing for Q1 2021, filed 26 Apr 2021.